Novo Nordisk
NVO
#51
Rank
$205.42 B
Marketcap
๐Ÿ‡ฉ๐Ÿ‡ฐ Denmark
Country
$89.56
Share price
-1.31%
Change (1 day)
25.40%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Revenue for Novo Nordisk (NVO)

Revenue in 2021 (TTM): $48.98 B

According to Novo Nordisk's latest financial reports the company's current revenue (TTM) is $48.98 B. In 2020 the company made a revenue of $48.99 B an increase over the years 2019 revenue that were of $44.43 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expences are substracted.

Revenue history for Novo Nordisk from 2001 to 2021

Year Revenue Change
2021 (TTM)$48.98 B-0.02%
2020$48.99 B10.26%
2019$44.43 B17.22%
2018$37.90 B6.72%
2017$35.51 B8.67%
2016$32.68 B8.83%
2015$30.03 B38.64%
2014$21.66 B13.75%
2013$19.04 B48.55%
2012$12.81 B17.6%
2011$10.90 B9.16%
2010$9.98 B18.99%
2009$8.39 B11.82%
2008$7.50 B9.02%
2007$6.88 B8.11%
2006$6.36 B14.91%
2005$5.54 B16.74%
2004$4.74 B8.83%
2003$4.36 B8.66%
2002$4.01 B0.74%
2001$3.98 B